English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

In the neuroscience landscape, there is no condition with higher unmet medical and societal need than Alzheimer's disease (AD). There are significant opportunities to improve upon symptomatic treatments in AD, and as yet, there are no treatments to modify (slow, stop, or prevent) underlying disease progression. Our goals are to discover new symptomatic AD therapies with improved efficacy and longevity; to complete definitive studies that refute or prove the amyloid hypothesis, potentially opening multiple avenues to new therapeutic modalities; and to initiate tests of novel mechanisms that can prevent tau pathology and neurodegeneration. It's a critical time in the testing of novel AD therapeutics-let's hope we succeed.

“It Ain’t Over ’til It’s Over”a—The Search for Treatments and Cures for Alzheimer’s Disease

“It Ain’t Over ’til It’s Over”^a—The Search for Treatments and Cures for Alzheimer’s Disease